PT - JOURNAL ARTICLE AU - Phil Davis AU - Rhonda J. Rosychuk AU - Jeffrey P Hau AU - Ivy Cheng AU - Andrew D. McRae AU - Raoul Daoust AU - Eddy Lang AU - Joel Turner AU - Jaspreet Khangura AU - Patrick T. Fok AU - Maja Stachura AU - Baljeet Brar AU - Corinne Hohl AU - on behalf of the CCEDRRN investigators, and for the Network of Canadian Emergency Researchers and the Canadian Critical Care Trials Group TI - Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted for Alternate Diagnoses AID - 10.1101/2021.09.23.21264036 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.23.21264036 4099 - http://medrxiv.org/content/early/2021/09/27/2021.09.23.21264036.short 4100 - http://medrxiv.org/content/early/2021/09/27/2021.09.23.21264036.full AB - Objectives To determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19, and identify risk factors for positive tests.Design Cohort from the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) registrySetting 30 acute care hospitals across CanadaParticipants Patients hospitalized for non-COVID-19 related diagnoses who were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between March 1, and December 29, 2020Main outcome Positive nucleic acid amplification test (NAAT) for SARS-CoV-2Outcome measure Diagnostic yieldResults We enrolled 15,690 consecutive eligible adults who were admitted to hospital without clinically suspected COVID-19. Among these patients, 122 tested positive for COVID-19, resulting in a diagnostic yield of 0.8% (95% CI 0.64% – 0.92%). Factors associated with a positive test included presence of a fever, being a healthcare worker, having a positive household contact or institutional exposure, and living in an area with higher 7-day average incident COVID-19 cases.Conclusions Universal screening of hospitalized patients for COVID-19 across two pandemic waves had a low diagnostic yield and should be informed by individual-level risk assessment in addition to regional COVID-19 prevalence.Trial registration NCT04702945SUMMARY BOXES Section 1: Universal screening of admitted patients for SARS-CoV-2 was implemented in many hospitals at the beginning of the pandemic. The Infections Diseases Society of America (IDSA) recommended avoiding universal screening of asymptomatic hospitalized patients in areas and times of low-COVID prevalence (defined as <2% prevalence) with very low certainty of evidence, based on studies of COVID-19 prevalence among asymptomatic individuals in the community.Section 2: This study supports IDSA recommendations to avoid universal screening for COVID-19 in times and areas of low COVID prevalence and identifies patient-level risk factors strongly associated with positive testing that should be considered for screening.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04702945Funding StatementThe Canadian Institutes of Health Research (447679), Ontario Ministry of Colleges and Universities (C-655-2129), Saskatchewan Health Research Foundation (5357), Genome BC (COV024) Foundation du CHU de Québec (Octroi No. 4007) and the Public Health Agency of Canada provided peer-reviewed funding. The BC Academic Health Science Network and BioTalent Canada provided non-peer reviewed funding. These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research ethics boards of all participating institutions approved this study with a waiver of informed consent for data collection and linkage. UBC REB: H20-01015All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe network endorses the guidance put forth by the World Health Organization to enable data sharing to optimize learning. We will prioritize data requests by network Members, but other scientists from non Member institutions are also welcome to request data access. Scientists who wish to access our data for use in their projects may request access from the CCEDRRN Executive Committee.